KIRKLAND, Wash.--(EON: Enhanced Online News)--Prevencio, Inc., a development stage company pioneering multiplex proteomic cardiac biomarker diagnostic tests for ruling out obstructive coronary artery disease in chest pain patients in the emergency room, today announced the appointment of H. Perry Fell, Ph.D. as Chairman of the Board and Rhonda F. Rhyne as President, Chief Executive Officer, and Board Director.
“With the escalating pressures to constrain healthcare expense and improve the quality of care, Prevencio is well-positioned for the Affordable Care Act (ACA) and to create long-term, sustainable value for health care, patients, and our shareholders.”
Dr. Fell is an industry leader with more than 40 years’ experience in research and development of biotechnology and pharmaceuticals. He co-founded Seattle Genetics (NASDAQ: SGEN) and served as Chairman and Chief Executive Officer of Seattle Genetics and NanoString Technologies (NASDAQ: NSTG). Dr. Fell was an Ernst & Young Entrepreneur of the Year award finalist for the Pacific Northwest.
Ms. Rhyne has spent the last 20 years in executive management for life science companies and specializes in taking innovative technologies from the research bench to successful commercialization. She was President of CardioDynamics, a publicly traded company, which sold to SonoSite, Inc. (now FujiFilm Holdings Corp., OTCPK: FUJIY) in 2009, then founded a consultancy company, Rhyne Life Sciences Consulting, specializing in early stage medical technology companies. Ms. Rhyne has received numerous industry awards including Ernst & Young Entrepreneur of the Year for Medical Technology, San Diego; Deloitte’s Technology Fast 50 Award for the 50 fastest-growing technology and life science companies in Southern California for nine consecutive years; and San Diego Business Journal’s Women Who Mean Business Award.
With the company’s recent conversion from a limited liability company (LLC) to a C Corporation, the company also announced the appointment of John Cramer, III, M.D., as Board Director. Dr. Cramer has served as Medical Director of the Hospital Team at Providence Regional Medical Center in Everett, Washington, and Associate Professor of Medicine at the University of Washington School of Medicine. Dr. Cramer also served as Network Medical Director for Aetna U.S. HealthCare.
“I am pleased to join Prevencio’s Board of Directors as I believe in the company’s mission and the clinical need for a safe, accurate, low-cost, and quick means of ruling out obstructive coronary artery disease in chest pain patients,” stated Dr. Fell. “We were fortunate to recruit Dr. Cramer and Ms. Rhyne as Directors and Rhonda as our Chief Executive Officer. John brings provider, as well as insurer, experience, and Rhonda has a successful history of developing and commercializing innovative medical technologies and brings depth and leadership to the management team.”
Rhyne added, “With the escalating pressures to constrain healthcare expense and improve the quality of care, Prevencio is well-positioned for the Affordable Care Act (ACA) and to create long-term, sustainable value for health care, patients, and our shareholders.”
Prevencio, a development stage company, is pioneering multiplex proteomic cardiac biomarker diagnostic tests for ruling out obstructive coronary artery disease in chest pain patients in the emergency room. The Company's proprietary HART™ Test will be a first-in-class product. The worldwide market potential for the HART™ Test is estimated to be $2 billion in recurring annual revenue. The hardware platform adds an additional $1 billion in worldwide market potential. For additional information, please refer to the Company's website at www.PrevencioMed.com.
Prevencio—Preventing the Preventable.™
Forward-Looking (Safe Harbor) Statement:
Except for the historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, size, potential, growth and penetration rates, the accuracy of which is necessarily subject to uncertainties and risks including the Company’s sole dependence on the HART technology, and various uncertainties characteristic of development stage companies. The Company does not undertake to update the disclosures contained in this press release.